These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials. Cucchiara B; Kasner SE; Tanne D; Levine SR; Demchuk A; Messe SR; Sansing L; Lees KR; Lyden P; Stroke; 2009 Sep; 40(9):3067-72. PubMed ID: 19608993 [TBL] [Abstract][Full Text] [Related]
5. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384 [TBL] [Abstract][Full Text] [Related]
6. A critical analysis of intra-arterial thrombolytic doses in acute ischemic stroke treatment. Hassan AE; Abd-Allah F; Chaudhry SA; Adil MM; Rostambeigi N; Qureshi AI Neurocrit Care; 2014 Aug; 21(1):119-23. PubMed ID: 23836425 [TBL] [Abstract][Full Text] [Related]
7. The iScore predicts efficacy and risk of bleeding in the National Institute of Neurological disorders and Stroke Tissue Plasminogen Activator Stroke Trial. Saposnik G; Demchuk A; Tu JV; Johnston SC; J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):876-82. PubMed ID: 23102741 [TBL] [Abstract][Full Text] [Related]
8. Intravenous tissue plasminogen activator for patients with minor ischemic stroke. Huisa BN; Raman R; Neil W; Ernstrom K; Hemmen TM J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):732-6. PubMed ID: 21531576 [TBL] [Abstract][Full Text] [Related]
10. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke. Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996 [TBL] [Abstract][Full Text] [Related]
11. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Zaidat OO; Suarez JI; Santillan C; Sunshine JL; Tarr RW; Paras VH; Selman WR; Landis DM Stroke; 2002 Jul; 33(7):1821-6. PubMed ID: 12105360 [TBL] [Abstract][Full Text] [Related]
12. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores. Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783 [TBL] [Abstract][Full Text] [Related]
13. Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience. Šaňák D; Jakubíček S; Černík D; Herzig R; Kunáš Z; Mikulík R; Ostrý S; Reif M; Rohan V; Tomek A; Veverka T J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2479-2483. PubMed ID: 29807757 [TBL] [Abstract][Full Text] [Related]